| Company Name: | AMAG Pharmaceuticals, Inc. | | Ticker Symbol: | AMAG | | | WWW Address: | www.amagpharma.com |
| CEO: | William K. Heiden | | No. of Employees: | 129 |
| Common Issue Type: | CS | | Business Description: | AMAG Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of Feraheme (ferumoxytol) Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA.
|
| | | Industry Information: | DRUGS - Diagnostic Support [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 21.93 |  -0.48 | 22.0 | 22.5 | 22.1 | 24.25 | 22.22 | 82433 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 473.1 | 21.6 | 0.67 | -0.78 | 0.00 | 0.0 | 0.0 | 25.67 - 13.38 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 22.40 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 473.1 | mil |
| Latest Shares Outstanding | 21.6 | mil |
| Earnings pS (EPS) | -0.78 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 661,845 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 12.5 | mil |
| Float as % of Shares Outstanding | 58.1 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 61.40 | % |
| Research & Devlopment (R&D) as % of Revenue | 29.90 | % |
| Gross Profit Margin | 90.2 | % |
| EBITDA Margin | -1.1 | % |
| Pre-Tax Profit Margin | -10.3 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | -3.3 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -4.8 | % |
| Current Ratio | 9.2 | |
| Leverage Ratio (Assets/Equity) | 1.4 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 10.12 | $ |
| Cash pS | 1.57 | $ |
| Book-Value pS | 7.94 | $ |
| Tangible Book-Value pS | 7.94 | $ |
| Cash Flow pS | -0.11 | $ |
| Free Cash Flow pS | 0.01 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.82 | |
| Price/Tangible Book Ratio | 2.82 | |
| Price/Cash Flow | -208.0 | |
| Price/Free Cash Flow | 0.0 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -11.7 | 89 | 1,578 | 7,528 |
| 4 Weeks | 25.67 | 21.55 | 21.89 | 2.3 | 98 | 1,583 | 28,499 |
| 13 Weeks | 25.67 | 15.90 | 16.32 | 37.3 | 126 | 1,408 | 87,310 |
| 26 Weeks | 25.67 | 14.22 | 14.74 | 52.0 | 129 | 1,113 | 136,911 |
| 52 Weeks | 25.67 | 13.38 | 13.90 | 61.2 | 128 | 999 | 246,758 |
| YTD | 25.67 | 15.00 | - | 52.3 | 131 | 1,203 | 117,887 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 24.63 | 24.68 | 22.82 | 18.23 | 17.66 | 0.67 | 0.27 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 122.19 | 82.5 | 30.18 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -49.42 | NA | -73.23 |
| R&D | 7.24 | NA | -7.95 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 15.5 | 15.5 | 39.4 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.40 | 0.40 | 2.86 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 85.78 |
| Current Ratio | 7.7 |
| Quick Ratio (Acid Test) | 7.1 |
| Liquidity Ratio (Cash) | 6.89 |
| Receivables Turnover | 13.1 |
| Average Collection Period | 27 |
| Working Capital/Equity | 128.1 |
| Working Capital pS | 10.30 |
| Cash-Flow pS | -0.50 |
| Free Cash-Flow pS | -0.06 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 4.41 |
| Financial Leverage Ratio (Assets/Equity) | 1.5 |
| Debt Ratio | 33.1 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 30.3 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 4.72 |
| Tobin's Q Ratio | 1.87 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -36.66 |
| Enterprise Value (EV)/Free Cash Flow | -283.73 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 2.82 |
| Price/Book Ratio - LTM | 2.82 |
| Price/Cash Flow Ratio | -208.0 |
| Price/Free Cash Flow Ratio - LTM | 0.0 |
| Price/Sales Ratio | 5.51 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 1.53 |
| Tangible Book Value pS - LTM | 7.94 |
| Book Value pS - LTM | 7.94 |
| Capital Invested pS | 8.01 |
| Cash pS - LTM | 1.57 |
| Cash Flow pS - LTM | -0.11 |
| Free Cash Flow pS - LTM | 0.01 |
| Earnings pS (EPS) | -0.78 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -1.41 |
| Free Cash Flow Margin 5YEAR AVG | -755.53 |
| Net Profit Margin | -19.6 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.49 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.49 |
| Return on Capital Invested (ROCI) | -9.7 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -35.6 |
| Assets Productivity | 0.30 |
| Return on Assets (ROA) | -6.5 |
| Return on Assets (ROA) - 5YEAR AVRG. | -26.6 |
| Gross Profit Margin | 90.2 |
| Gross Profit Margin - 5YEAR AVRG. | 94.3 |
| EBITDA Margin - LTM | -1.1 |
| EBIT Margin - LTM | -10.3 |
| Pre-Tax Profit Margin | -20.6 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 4.9 |
| Effective Tax Rate - 5YEAR AVRG. | 1.7 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 626 |
| Revenue per Employee | 661,845 |
| Net Income per Employee | -129,845 |
| Average Collection Period | 28 |
| Receivables Turnover | 13.1 |
| Day's Inventory Turnover Ratio | 598 |
| Inventory Turnover | 0.6 |
| Inventory/Sales | 14.6 |
| Accounts Payble/Sales | 4.12 |
| Assets/Revenue | 3.33 |
| Net Working Capital Turnover | 0.39 |
| Fixed Assets Turnover | 22.73 |
| Total Assets Turnover | 0.3 |
| Revenue per $ Cash | 1.84 |
| Revenue per $ Plant | 25.90 |
| Revenue per $ Common Equity | 0.49 |
| Revenue per $ Capital Invested | 0.49 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 62.2 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 144.1 |
| Research & Devlopment (R&D) as % of Revenue | 39.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 39.0 |
|
|  
|
| |
 |  |
